We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)

Expanded access is no longer available for this treatment.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01689376
First Posted: September 21, 2012
Last Update Posted: August 16, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Bayer
July 18, 2012
September 21, 2012
August 16, 2016
 
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
The purpose of this Managed Access Program is to provide regorafenib to patients diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy.
This "Managed Access Program" covers the different types of programs in the participating countries (including compassionate use program, named patient program, cohorts e.g. ATU in France, etc).
Expanded Access
Drug: Regorafenib (BAY73-4506)
160 mg BAY73-4506, 3 weeks on drug, 1 week off drug
Not Provided
 
No longer available
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01689376
Bayer
Bayer
Not Provided
Study Director: Bayer Study Director Bayer
Bayer
August 2016